ICT still at risk of demotion, warn administrators
Inverness Caledonian Thistle's joint administrators warn the club remains at risk of being demoted - despite Saturday's crucial win over Arbroath.
BDO was appointed in October to oversee ICT's finances and also find a new owner after the club ran up large debts.
Inverness' 3-0 victory ensured the League 1 club avoided a potential end-of-season relegation battle.
But BDO said shareholders now needed to agree to terms set out by Alan Savage, the preferred bidder to buy the club, to prevent the deal from falling through.
Mr Savage's conditions include that 100% of voting shares transfer to him.
He has also asked that all loan creditors be written off, and that an agreement is reached on ownership of land around the stadium.
Are Inverness Caley Thistle on the rise after a fall?
Offer to take Dumbarton out of administration withdrawn
BDO said a meeting on 22 May could lead to ICT exiting administration.
A spokesperson said: "However, these conditions need to be in place prior to the meeting and we would encourage all shareholders in particular to complete and return their stock transfer forms as soon as possible.
"We would remind any shareholder who may be minded not to agree to the proposal that this may result in the offer being withdrawn, the assets sold to another entity and the club - should it survive - being demoted outside of the league structure."
The spokesperson added that if this happened all shares could eventually end up being "redundant".
More stories from the Highlands and Islands
News from the Highlands and Islands on BBC Sounds
BDO congratulated the team on Saturday's win and said it was something everyone at the club should be proud of.
Inverness had been facing the threat of relegation after it was deducted 15 points by the league as punishment for its financial situation.
But the team has taken club from the bottom of the league to seventh place.
Saturday's away game against Montrose will be ICT's last game of this season.
BDO's warning has come as a proposal to take Inverness' League 1 rivals Dumbarton out of administration and pay their creditors in full has collapsed.
On 15 April, administrators Quantuma announced a deal with Oxford-based Gareth Phillips that would wipe out the club's debt, with working capital made available for next season.
Now it has said that Mr Phillips had withdrawn his offer due to ill-health.
Quantuma said "other credible parties" remained interested in taking over the club.
ICTFC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Xabi Alonso makes first major call on Real Madrid tenure
Real Madrid presented new manager Xabi Alonso to the media last week to plenty of fanfare, with the Basque manager's much-awaited arrival met positively by the fanbase. During his opening statements, he give little away about how his team would be setting up. Alonso stayed clear of defintitive statements on how his side would play, or what players would be there to play it, with the future of Rodrygo Goes thought to be up in the air – the Brazilian has since informed Los Blancos that he is keen to stay. The ex-Bayer Leverkusen man did note that he would be moving Jude Bellingham further back in midfield though, and that he wanted his side to be protagonists. Xabi Alonso makes Real Madrid formation decision According to Marca, Alonso has decided to park his preferred 3-5-2 formation at Leverkusen for the time being, and will work towards a 4-3-3 system for the time being. Previous reports had noted that Alonso was not thinking about making a radical change before the Club World Cup, and would reassess afterwards, and the Madrid-based daily explain that the coaching staff feel the current squad his not set up to play three at the back, although the 4-3-3 will not be the only system in mind. Image via Marca Vinicius Junior conversation incoming One of the things that has worried Alonso most after a detailed analysis of Los Blancos' recent games is the defensive attitude of some of his players, and Alonso is keen to emphasize that defending is required from the whole team. If that 4-3-3 does come into place, Vinicius Junior will likely be on the left wing, and he will hold a conversation with the Brazilian to make that clear to him. A system that benefits…? In theory, this system would benefit Rodrygo Goes more than anyone, who together with Brahim Diaz has a more natural position in a 4-3-3 than a 3-5-2. At the very least, they would have a clearer path to a starting spot. It is news that may be less encouraging for the likes of Dai Carvajal, Antonio Rudiger, Eder Militao and Raul Asencio, who with new signings arriving in their positions, face increased competition without increased spaces in the starting XI.
